Last update 21 Nov 2024

68Ga-Edotreotide

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

68Ga-DOTATOC, 68Ga-Edotreotide, Ga-68 DOTATOC

+ [11]

Target

SSTR

Mechanism

SSTR antagonists(Somatostatin receptor antagonists), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Neuroendocrine TumorsGastro-Enteropancreatic Neuroendocrine TumorEndocarditis, Bacterial

Inactive Indication

Carcinoid TumorMedulloblastomaNeuroblastoma+ [2]

Originator Organization

Advanced Accelerator Applications SA

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.Tianjin Hengrui Pharmaceutical Co., Ltd

Advanced Accelerator Applications SA

+ [3]

Inactive Organization

University of Iowa

Icahn School of Medicine at Mount Sinai

Drug Highest PhaseApproved

First Approval Date

EU (08 Dec 2016),

Gastro-Enteropancreatic Neuroendocrine Tumor

RegulationOrphan Drug (US)

Structure

Molecular FormulaC65H92N14O18S2

InChIKeyRZHKDBRREKOZEW-AAXZNHDCSA-N

CAS Registry204318-14-9

Boost your research with our ADC technology data.

view full example data

Gene Sequence

Sequence Code 525984615

Clinical Trials associated with 68Ga-Edotreotide

NCT04298541 / Not yet recruitingPhase 2IIT

SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

The goal of this study is to propose the first direct comparison of Ga-68-DOTATATE PET/CT or PET/MR and Ga-68-DOTATOC PET/CT in patients with meningioma.

Start Date01 Nov 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

NCT06611891 / Not yet recruitingPhase 3IIT

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

Start Date01 Oct 2024

Sponsor / Collaborator

Centre Hospitalier Universitaire de Grenoble

CTR20233293 / RecruitingPhase 3

镓[68Ga]伊索曲肽用于生长抑素受体过表达的高分化胃肠胰神经内分泌瘤 PET/CT 诊断的前瞻性、单臂、盲态阅片、自身对照 III 期临床研究

[Translation] A prospective, single-arm, blinded, self-controlled phase III clinical study of gallium [68Ga] esotreotide for the PET/CT diagnosis of well-differentiated gastroenteropancreatic neuroendocrine tumors with somatostatin receptor overexpression

评价镓[68Ga]伊索曲肽用于高分化胃肠胰神经内分泌瘤PET/CT成像的诊断效能。

[Translation]

To evaluate the diagnostic efficacy of gallium [68Ga] esoprotreotide for PET/CT imaging of well-differentiated gastrointestinal and pancreatic neuroendocrine tumors.

Start Date22 Feb 2024

Sponsor / Collaborator

Tianjin Hengrui Pharmaceutical Co., Ltd

100 Clinical Results associated with 68Ga-Edotreotide

100 Translational Medicine associated with 68Ga-Edotreotide

100 Patents (Medical) associated with 68Ga-Edotreotide

262

Literatures (Medical) associated with 68Ga-Edotreotide

01 Nov 2024·Cancer Biotherapy and Radiopharmaceuticals

Advancing Cancer Theranostics Through Integrin αVβ3-Targeted Peptidomimetic IAC: From Bench to Bedside

Article

Author: Rana, Nivedita ; Satz, Stanley ; Mittal, Bhagwant Rai ; Chopra, Sejal ; Pandey, Somit ; Laroiya, Ishita ; Stabin, Micheal G. ; Kumar, Rajender ; Kaur, Gurvinder ; Shukla, Jaya ; Chadha, Vijayta D. ; Rather, Imran

Introduction: The expression of alpha-five beta-three (αVβ3) integrins is upregulated in various malignancies undergoing angiogenesis. The development of integrin antagonists as diagnostic probes makes the αVβ3 integrin a suitable candidate for targeting tumor angiogenesis. The goal of this study was to optimize the radiolabeling and evaluate the potential of conjugated integrin antagonist carbamate (IAC), a peptidomimetic, as a theranostic radiopharmaceutical for targeting tumor angiogenesis. Methodology: Radiolabeling of DOTAGA [2,2',2"-{10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl} triacetic-acid]-IAC with [⁶⁸Ga]Ga, [¹⁷⁷Lu]Lu, and [²²⁵Ac]Ac was optimized. The binding affinity (K_d) of DOTAGA-IAC for the αVβ3 receptor and cancer cell lines was quantified. The biodistribution studies were conducted in healthy Wistar rats. Dosimetry analysis was performed on [¹⁷⁷Lu]Lu-DOTAGA-IAC distribution data. A pilot study of [⁶⁸Ga]Ga-DOTAGA-IAC and [¹⁸F]FDG Positron Emission Tomography (PET/CT) imaging was performed in five patients with histopathologically confirmed breast cancer. PET/CT findings were compared between [⁶⁸Ga]Ga-DOTAGA-IAC and [¹⁸F]FDG in these patients. Results: Radiopharmaceuticals were prepared with high radiochemical purity (>99.9%). K_d and B_max measurements were 15.02 nM and 417 fmol for αVβ3 receptor protein: 115.7 nM and 295.3 fmol for C6 glioma cells. Biodistribution studies in rats suggested the excretion via kidneys and partially through the hepatobiliary route. The effective dose of [¹⁷⁷Lu]Lu-DOTAGA-IAC was found to be 0.17 mSv/MBq. The dynamic study in patients revealed the optimal imaging time to be 30-35 mins postadministration. Out of the cohort, [⁶⁸Ga]Ga-DOTAGA-IAC detected the primary lesions in all five patients with a mean standard uptake value (SUV_max) of 3.94 ± 0.58 compared with [¹⁸F]FDG (SUV_max 13.8 ± 6.53). Conclusion: The study demonstrates that DOTAGA-IAC exhibits strong binding to αVβ3 integrin, positioning it as a promising PET agent for assessing primary and metastatic cancers. The outcomes from the pilot study suggest the potential of [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT in breast carcinoma diagnosis. While recognizing the theranostic potential of DOTAGA-IAC for αVβ3 integrin-expressing tumors, further clinical investigations are warranted to comprehensively assess therapeutic efficacy.

01 Nov 2024·In Vivo

⁵²Mn-labelled Beta-cyclodextrin for Melanoma Imaging: A Proof-of-concept Preclinical Study

Article

Author: FENYVESI, FERENC ; Fenyvesi, Ferenc ; Trencsényi, György ; OPPOSITS, GÁBOR ; Jószai, István ; Opposits, Gábor ; Kálmán-Szabó, Ibolya ; KÁLMÁN-SZABÓ, IBOLYA ; Képes, Zita ; Hajdu, István ; HAJDU, ISTVÁN ; SASS, TAMÁS ; Szabó, Judit P ; Esze, Regina ; SZIKRA, DEZSŐ ; TRENCSÉNYI, GYÖRGY ; ESZE, REGINA ; KÉPES, ZITA ; Szikra, Dezső ; Sass, Tamás ; SZABÓ, JUDIT P. ; JÓSZAI, ISTVÁN

BACKGROUND/AIMAs prostaglandin E2 (PGE2) and its receptors (EP2) are over-expressed on tumor cells and microenvironment, radiolabeled cyclodextrins targeting such biomolecules are valuable vector candidates in molecular cancer diagnostics. Using experimental melanoma models, we evaluated the in vivo imaging behavior of novel Manganese-52-labeled (⁵²Mn) randomly methylated beta-cyclodextrin ([⁵²Mn]Mn-DOTAGA-RAMEB) and compared it with the following well-established tumor-specific probes: melanocortin-1 receptor (MC1-R)-affine [⁶⁸Ga]Ga-DOTA-NAPamide and PGE2 selective [⁶⁸Ga]Ga-DOTAGA-RAMEB cyclodextrin.MATERIALS AND METHODSPost-injection of [⁶⁸Ga]Ga-DOTA-NAPamide, [⁶⁸Ga]Ga-DOTAGA-RAMEB, and [⁵²Mn]Mn-DOTAGA-RAMEB into MC1-R positive B16F10 melanoma-bearing mice, tumor radio-pharmaceutical uptake was quantified in vivo and ex vivo using preclinical positron emission tomography (PET) and high-performance gamma counter.RESULTSAlthough all tracers performed well in tumor identification, the highest standardized uptake values were detected in the [⁶⁸Ga]Ga-DOTA-NAPamide scans. Corresponding to the ex vivo data, meaningful [⁵²Mn]Mn-DOTAGA-RAMEB accumulation 1 h post-injection confirmed the tumor-targeting potential of the tracer. Temporal changes in PGE2/EP2 expression of the neoplasms may explain the significant differences observed between the tumor uptake of the two cyclodextrin probes and that of the ⁵²Mn-labelled compound measured 1 h, 4 h, and 3 days post-injection (p≤0.01, p≤0.05).CONCLUSIONAlthough further pharmacokinetical optimization may be required, ⁵²Mn-labelled cyclodextrin holds potential in melanoma diagnostics and the PET-based longitudinal assessment of tumor-associated PGE2/EP2 expression.

01 Sep 2024·Journal of Nuclear Medicine

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up

Article

Author: Sarnelli, Anna ; Manuela, Monti ; Arpa, Donatella ; Severi, Stefano ; Grassi, Ilaria ; Fabbri, Lucia ; Nicolini, Silvia ; Azzali, Irene ; Calabro, Luana ; Amadori, Elena ; Bongiovanni, Alberto ; Marini, Irene ; Riva, Nada ; Di Iorio, Valentina ; Tosatto, Luigino ; Di Meco, Francesco ; Matteucci, Federica ; Sansovini, Maddalena ; Bartolini, Daniela ; Paganelli, Giovanni ; Gurrieri, Lorena ; Ranallo, Nicoletta

Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with ⁶⁸Ga-DOTA-octreotide and peptide receptor radionuclide therapy (PRRT) with ⁹⁰Y/¹⁷⁷Lu-DOTA-octreotide are currently possible options within experimental protocols or as compassionate use in small patient groups. Methods: From October 2009 to October 2021, 42 meningioma patients with radiologic recurrence after standard therapies were treated with ⁹⁰Y-DOTATOC (dosage of 1.1 or 5.5 GBq) or with ¹⁷⁷Lu-DOTATATE (dosage of 3.7 or 5.5 GBq) in a mean of 4 cycles. All patients showed intense uptake at diagnostic ⁶⁸Ga-DOTATOC PET/CT or in an ¹¹¹In-octreotide scan. Results: Of 42 patients treated, 5 patients received ⁹⁰Y-DOTATOC with a cumulative activity of 11.1 GBq and 37 patients received ¹⁷⁷Lu-DOTATATE with a cumulative activity of 22 GBq. The disease control rate was 57%. With a median follow-up of 63 mo, median progression-free survival was 16 mo, and median overall survival was 36 mo. Retreatment ¹⁷⁷Lu-PRRT was performed in 6 patients with an administered median activity of 13 GBq in a mean of 5 cycles. With a 75.8-mo follow-up, median progression-free survival and overall survival were 6.5 and 17 mo, respectively. Only 1 patient discontinued the treatment because of grade 3 platelet toxicity. A rapidly transient grade 2 neutropenia was recorded in 1 retreated patient. Conclusion: PRRT in patients with advanced meningiomas overexpressing somatostatin receptor 2 was active and well tolerated, showing a 57% disease control rate. Furthermore, PRRT could represent a potential retreatment option. Further studies, also in combination with other treatments, are warranted.

News (Medical) associated with 68Ga-Edotreotide

06 Jun 2024

·firstwordpharma.com

Key radioisotope supplier ITM raises over $200M to fund pipeline, boost manufacturing

As radiopharmaceuticals continue their hot streak, one of the few players with a marketed product, ITM Isotope Technologies Munich, has pulled in additional funding to help advance its lead pipeline candidate. The firm has secured a new investment of €188 million ($204 million), led by previous backer Temasek, with participation from BlackRock, Qatar Investment Authority and ATHOS.ITM currently markets EndolucinBeta, which uses lutetium-177 (177Lu) for radiolabelling of other medicines, and TOCscan/Sogacin, which uses gallium (68Ga) edotreotide for diagnosing neuroendocrine tumours (NETs). While the two products are sold in a handful of European countries, ITM's pipeline has loftier ambitions and is stacked with a number of targeted radionuclide therapies based not only on 177Lu and 68Ga, but also on actinium-225 (225Ac), fluorine-18 and terbium-161.Phase III nearing completionIts lead asset, ITM-11 (177Lu-edotreotide), is nearing the end of Phase III testing in gastroenteropancreatic NETs (GEP-NETs). The late-stage COMPETE study is evaluating ITM-11 in patients with Grade 1 - 2 GEP-NETs, while the COMPOSE trial is for patients with well-differentiated high Grade 2 - 3 GEP-NETs. With this in mind, ITM will use some of the proceeds from the latest financing to “prepare commercial readiness” of ITM-11.“We have reached key milestones since our last financing round including advancing our pipeline with novel targets in multiple oncology indications,” remarked CEO Steffen Schuster. Almost exactly a year ago to the day, ITM announced a haul of €255 million – again led by Temasek – building on the €58 million it raised in 2022 and €114 million it secured in the prior year. Key supplier to NovartisAside from its internal pipeline, ITM recently launched a joint venture to produce 225Ac, while it has several supply agreements in place for 177Lu, including with Telix Pharmaceuticals and Endocyte, the latter now part of Novartis. In fact, the Swiss drugmaker is one of the key players in the radiopharmaceutical space, with its marketed products including Lutathera (177Lu dotatate) for GEP-NETs and the prostate cancer therapy Pluvicto (177Lu vipivotide tetraxetan). However, Novartis itself has faced production issues for Pluvicto, and only recently gained clearance for a new US radioligand manufacturing facility to help it keep up with demand.ITM plans to put some of the new funding toward ramping up its in-house manufacturing capacities for 177Lu and expand these to new radioisotopes including 225Ac. ITM said it will use the radioisotopes not only for its own pipeline, but also provide them to its global supply network. For related analysis, see Vital Signs: Mapping the slim pickings in radiopharmaceuticals.

Phase 3OligonucleotideIND

16 Apr 2024

·www.prnewswire.com

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

SPRINGFIELD, N.J., April 16, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing advances Evergreen's novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to meet growing client demand. "We have been advancing our discovery pipeline and are excited to take the next step in development," commented James Cook, CEO. "As we continue to work with the FDA on approval of our Ga-68 DOTATOC diagnostic kit, this new funding will enable us to rapidly progress our novel theragnostic pair, EVG-321, into clinical trials. In addition, our CDMO business is continuing to build momentum as we bring on new customers and expand our efforts with existing ones. We appreciate the trust given to us by our existing and new shareholders in advancing our priorities." "We have tracked Evergreen since the company's inception and are excited to partner with James and his team as they bring best- and first-in-class candidates into the clinic, broaden their top-tier radiopharma drug discovery efforts, prepare for commercial launch of their diagnostic product, and further capitalize on the highly specialized expertise required to build and run a radiopharma CDMO," said Patrick Lally, Partner at Petrichor. Stefano Buono, chairman of LIFTT and founder and former CEO of Advanced Accelerator Applications (AAA) noted, "the radioligand therapy industry is advancing rapidly. Our investment in Evergreen Theragnostics deepens our commitment to this exciting area with a company that is well-positioned to succeed." Evergreen has established a lean and experienced team of scientific, medical, commercial, and operational leaders and employees to continue to develop our capabilities. Over the next months, Evergreen will continue to plan for the launch of our diagnostic agent Octevy™, subject to approval by the FDA. Evergreen Discovery also intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG-321 and Gallium-68 (68Ga) EVG-321, a novel radiopharmaceutical theragnostic pair, which, if successful, could offer new hope to patients with small cell lung cancer. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing and commercialization. For more information, please visit . About Petrichor Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 125 investments representing more than $6 billion in invested capital and has held over 55 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies. For more information on Petrichor, please see or contact the firm at [email protected]. About LIFTT LIFTT is an Italian Venture Capital operating in every industry with a focus on deep-tech. To date it has raised €103,7M and completed 50 investments in innovative start-ups. While generating value for its shareholders, LIFTT supports the creation of businesses, development, employment, and economic growth, through the implementation of an ethical and transparent governance model. To learn more, please visit For further information, please contact: James Cook President & CEO [email protected] SOURCE Evergreen Theragnostics, Inc.

23 Jun 2023

·www.prnewswire.com

Jubilant Radiopharma and Evergreen Theragnostics Announce Collaboration for the Sale and Distribution of Neuroendocrine Tumor Diagnostic OCTEVY™, (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023

YARDLEY, Pa., and SPRINGFIELD, N.J., June 23, 2023 /PRNewswire/ -- Jubilant Draximage Inc. (dba, Jubilant Radiopharma™), a Jubilant Pharma Company, through it's Radiopharmacy business division which maintains the second largest nuclear medicine pharmacy network in the US, and Evergreen Theragnostics, Inc., a radiopharmaceutical company focused on improving the available options for cancer patients, announced a new agreement for Jubilant's radiopharmacy business to prepare, sell, and distribute doses of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection) to positron emission tomography (PET) customers across the US. OCTEVYTM is pending approval by the United States Food & Drug Administration (FDA), which is expected in 2H 2023. OCTEVY™ is currently under evaluation by the FDA as a potential radioactive diagnostic agent indicated for use with PET for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. If approved, OCTEVY™ can provide a new imaging option for healthcare providers to aid in the management of NETs in their patients. Under the terms of the agreement, upon regulatory approval, Jubilant will reconstitute, radiolabel, and deliver OCTEVY™ doses ordered by hospitals and independent PET imaging centers in the United States. _________________________________________________ About Neuroendocrine Tumors Neuroendocrine tumors (NETs) are a diverse set of cancers that originate in neuroendocrine cells, which are cells that carry messages from the nervous system to the endocrine system. Because neuroendocrine cells are located in many organs, NETs are often heterogeneous in their symptoms and therefore difficult to diagnose. The incidence of NETs are low, but are increasing, likely in part due to increased diagnosis of the disease. Once a patient has been identified as having a NET, they will often undergo a PET scan to localize and state the cancer, which will help the care team identify the best course of treatment. About OCTEVY™ OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), is currently under evaluation by FDA as a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. OCTEVY™ is supplied as a 2-vial kit to radiopharmacies which allows for direct preparation of Ga 68 DOTATOC injection with the eluate of Gallium from an on-site generator at the radiopharmacy. OCTEVY™ is not currently approved by the FDA and is not yet available for sale in the United States. About Jubilant Radiopharmacy Business Jubilant's Radiopharmacy business is the second largest nuclear medicine pharmacy network in the United States, owns and operates 46 radiopharmacies across 21 states, offering an extensive portfolio of nuclear imaging products. Jubilant's radiopharmacy business only supply FDA approved, high quality radiopharmaceuticals. We provide highly customized customer solutions and exceptional service to our customers and the patients they serve. For more information, please visit About Evergreen Theragnostics Evergreen Theragnostics, headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility, is focused on improving the available options for cancer patients using radiopharmaceuticals. Founded in 2019, the company is engaged in three core areas: CDMO, Products, and Drug Discovery. The CDMO business unit offers research and commercial scale, centralized production capacity for therapeutic and long-lived diagnostic products. The Products business unit develops and commercializes Evergreen-owned assets. Evergreen Discovery is focused on developing novel radiopharmaceuticals for cancer therapy, focusing on unprecedented and first-in-class radiopharmaceuticals. For more information, please visit . CONTACTS: Evergreen Theragnostics, Inc. James Cook Chief Executive Officer [email protected] Jubilant Radiopharma Renato Leite President [email protected] SOURCE Evergreen Theragnostics, Inc.

Diagnostic ReagentsClinical Study

100 Deals associated with 68Ga-Edotreotide

External Link

KEGG	Wiki	ATC	Drug Bank
-	68Ga-Edotreotide	V09IX	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuroendocrine Tumors	US	UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER	21 Aug 2019
Gastro-Enteropancreatic Neuroendocrine Tumor	-	ITM Isotopen Technologien München AG	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carcinoid Tumor	NDA/BLA	US	University of Iowa	01 Sep 2015
Somatostatinoma	NDA/BLA	US	Icahn School of Medicine at Mount Sinai	01 Dec 2014
Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Nov 2023
Endocarditis, Bacterial	Phase 2	FR	Centre Hospitalier Regional de Nancy	16 May 2022
Carcinoid Tumor	Discovery	US	University of Iowa	01 Sep 2015
Medulloblastoma	Discovery	US	University of Iowa	01 Sep 2015
Neuroblastoma	Discovery	US	University of Iowa	01 Sep 2015
Somatostatin Receptor-Positive Neuroendocrine Tumor	Discovery	US	University of Iowa	21 Feb 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05448157 (RGS GEP-NET, Pubmed)	Phase 2	Neuroendocrine Tumors 68Ga-DOTA-TOC	20	68Ga-DOTA-TOC	wspyfsxrct(gslhnqroxh) = voiaqkafyj txxdoxggaq (vdrdqtghmz ) View more	Positive	23 Apr 2024
NCT01869725 (CTgov)	Phase 2	Somatostatinoma \| Neuroblastoma \| Medulloblastoma	68	contrast-enhanced magnetic resonance imaging+gallium Ga 68-edotreotide	srmfqschjq(ipwojiqhbe) = rylhxzyyta mjhxexniih (trfxzncony, fscmnljgre - zlhufinqpk) View more	-	22 Sep 2021
SNMMI2021	Not Applicable	-	-	68 Ga-DOTA-TOC (Patients with normal serum glucose level)	ciluunropb(mqomcgijcl) = hdkjtanptb epqnobnptg (xaibvdraon, 5.238)	-	18 May 2021
NCT01619865 (GA-68, CTgov)	Phase 1/2	Carcinoid Tumor \| Neuroblastoma \| Medulloblastoma \| Somatostatin Receptor-Positive Neuroendocrine Tumor	223	68Ga-DOTATOC PET/CT	zggqszeqax(idoxkwcnbl) = ddeyxkibcr semrvxpbuk (vraqafnjnb, xwomhvmzgc - jvqstwvvjl) View more	-	02 Feb 2021
NCT03136328 (CTgov)	Phase 3	Neuroendocrine Tumors	11	68Ga-DOTATOC	mbtyauqdjs(mpgfovgwhg) = lmmpezoelc xbdbnotgsb (itpdqoafms, bfnuraceae - ydxhianfua) View more	-	30 Jan 2019
SNMMI2018	Not Applicable	-	-	68 Ga-DOTATOC (Galli Eo® 68Ge/68Ga generator)	zyceuosmcf(uqsbyyiotr) = xygiqtdcob mtfvxntvhz (sgtjfrgehn ) View more	-	23 May 2018
SNMMI2018	Not Applicable	-	-	68 Ga-DOTATOC (GRP 3V synthesizer)	zyceuosmcf(uqsbyyiotr) = eqrbehfcho mtfvxntvhz (sgtjfrgehn ) View more	-	23 May 2018
IND 123015;GCO 14-2008 (SNMMI2017)	Not Applicable	Neuroendocrine Tumors	63	68Ga-DOTA-TOCGa-68 DOTATOC (68Ga-DOTA-TOC PET/CT)	(zcvrvxblrw) = idbueotrfb kqdrkrtvju (ntscfijzsj ) View more	Positive	24 May 2017
IND 123015;GCO 14-2008 (SNMMI2017)	Not Applicable	Neuroendocrine Tumors	63	Ga-68 DOTATOC (Conventional imaging (In-111Octreotide, MRI, CT))	(zcvrvxblrw) = vrstzcvsci kqdrkrtvju (ntscfijzsj ) View more	Positive	24 May 2017
SNMMI2016	Not Applicable	Neuroendocrine Tumors	-	64Cu-DOTATATE	lwqrngghcc(vyjcjgqgqt) = renkzbfixz ilpngqnazq (tvefsxankg ) View more	-	24 May 2016
SNMMI2016	Not Applicable	Neuroendocrine Tumors	-	68Ga-DOTATOC	lwqrngghcc(vyjcjgqgqt) = piknhhysht ilpngqnazq (tvefsxankg ) View more	-	24 May 2016
SNMMI2016	Not Applicable	Neuroendocrine Tumors	-	68Ga-DOTA-TOC18F-FDGTA-TOC (18F-FDG-PET/CT)	fyjaqigbmi(zbnmipihla) = wocexilbca pggqqiubwh (dhjvrtkxac )	-	24 May 2016
SNMMI2015	Not Applicable	-	-	68Ga-DOTATOC	jgymjnogtv(ughhbcebry) = skwstpeips xmietefvwf (pvkrqfsogp )	-	15 May 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis